HL
GMAB icon

Harding Loevner’s Genmab GMAB Stock Holding History

Harding Loevner’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.9M Sell
3,086,318
-145,283
-4% -$3.86M 0.82% 32
2026
Q1 		$86.7M Sell
3,231,601
-138,542
-4% -$4.15M 0.89% 36
2025
Q4 		$104M Sell
3,370,143
-114,344
-3% -$3.56M 0.91% 35
2025
Q3 		$107M Buy
3,484,487
+561,048
+19% +$13.7M 0.78% 38
2025
Q2 		$60.4M Buy
2,923,439
+42,613
+1% +$875K 0.41% 55
2025
Q1 		$56.4M Buy
2,880,826
+637,434
+28% +$13.4M 0.43% 52
2024
Q4 		$46.8M Sell
2,243,392
-823,550
-27% -$18.1M 0.32% 52
2024
Q3 		$74.7M Buy
3,066,942
+299,137
+11% +$8M 0.43% 51
2024
Q2 		$69.6M Sell
2,767,805
-526,923
-16% -$14.9M 0.38% 58
2024
Q1 		$98.5M Buy
3,294,728
+4,833
+0.1% +$142K 0.61% 49
2023
Q4 		$97.6M Buy
3,289,895
+85,665
+3% +$2.69M 0.55% 56
2023
Q3 		$113M Buy
3,204,230
+3,036,109
+1,806% +$116M 0.75% 49
2023
Q2 		$6.39M Sell
168,121
-2,029
-1% -$80.9K 0.04% 62
2023
Q1 		$6.43M Buy
170,150
+47,238
+38% +$1.82M 0.04% 68
2022
Q4 		$5.2M Sell
122,912
-6,308
-5% -$260K 0.03% 74
2022
Q3 		$4.15M Sell
129,220
-1,061
-0.8% -$37.3K 0.03% 73
2022
Q2 		$4.24M Sell
130,281
-6,667
-5% -$216K 0.03% 74
2022
Q1 		$4.96M Buy
136,948
+1,827
+1% +$62.7K 0.03% 77
2021
Q4 		$5.34M Buy
135,121
+3,098
+2% +$129K 0.02% 79
2021
Q3 		$5.77M Sell
132,023
-267
-0.2% -$12K 0.02% 77
2021
Q2 		$5.4M Buy
132,290
+13,012
+11% +$502K 0.02% 76
2021
Q1 		$3.92M Sell
119,278
-5,050
-4% -$190K 0.02% 80
2020
Q4 		$5.06M Buy
+124,328
New +$4.65M 0.02% 71

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Harding Loevner's GMAB Position: Q2 2026 in Review

Harding Loevner reduced its Genmab (GMAB) stake by 4.5% in Q2 2026, selling an estimated $3.86M and leaving 3,086,318 shares worth $86.9M. The position accounts for 0.82% of the portfolio, ranked #32.

Harding Loevner first reported a position in GMAB in Q4 2020 and has held it in 23 quarters since. The position peaked at $113M in Q3 2023. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Harding Loevner held 3,086,318 shares of Genmab worth $86.9M as of Q2 2026.
  • Harding Loevner sold 145,283 Genmab shares in Q2 2026, an estimated $3.86M.
  • Genmab made up 0.82% of Harding Loevner's portfolio in Q2 2026, its #32 holding.
  • Harding Loevner first reported a position in Genmab in Q4 2020 and has held it in 23 quarters since.
  • Harding Loevner's Genmab position peaked at $113M in Q3 2023.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Harding Loevner's 13F filing for Q2 2026, filed 14 Aug 2026.